Achilles Therapeutics Plc Stock Fundamentals
| ACHL Stock | USD 1.43 0.01 0.70% |
Achilles Therapeutics PLC fundamentals help investors to digest information that contributes to Achilles Therapeutics' financial success or failures. It also enables traders to predict the movement of Achilles Stock. The fundamental analysis module provides a way to measure Achilles Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Achilles Therapeutics stock.
At this time, Achilles Therapeutics' Interest Expense is quite stable compared to the past year. Tax Provision is expected to rise to about 39.2 K this year, although the value of Net Loss is projected to rise to (60.9 M). Achilles | Select Account or Indicator |
Achilles Therapeutics PLC Company Shares Owned By Insiders Analysis
Achilles Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Achilles Therapeutics Shares Owned By Insiders | 6.51 % |
Most of Achilles Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Achilles Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 6.51299999999999% of Achilles Therapeutics PLC are shares owned by insiders. This is 57.09% lower than that of the Biotechnology sector and 54.07% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 35.45% higher than that of the company.
Achilles Therapeutics PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Achilles Therapeutics's current stock value. Our valuation model uses many indicators to compare Achilles Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Achilles Therapeutics competition to find correlations between indicators driving Achilles Therapeutics's intrinsic value. More Info.Achilles Therapeutics PLC is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Achilles Therapeutics' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Achilles Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Achilles Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Achilles Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Achilles Therapeutics could also be used in its relative valuation, which is a method of valuing Achilles Therapeutics by comparing valuation metrics of similar companies.Achilles Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Achilles Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Achilles Therapeutics from analyzing Achilles Therapeutics' financial statements. These drivers represent accounts that assess Achilles Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Achilles Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 672.3M | 143.6M | 35.2M | 35.5M | 40.9M | 38.8M | |
| Enterprise Value | 510.4M | (110.5M) | (129.5M) | (91.4M) | (105.1M) | (99.8M) |
Achilles Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (21.35 M) | ||||
| Shares Outstanding | 41.1 M | ||||
| Shares Owned By Insiders | 6.51 % | ||||
| Shares Owned By Institutions | 86.00 % | ||||
| Number Of Shares Shorted | 797.85 K | ||||
| Price To Earning | 0.49 X | ||||
| Price To Book | 0.57 X | ||||
| EBITDA | (70.44 M) | ||||
| Net Income | (69.94 M) | ||||
| Cash And Equivalents | 201.6 M | ||||
| Cash Per Share | 4.94 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.45 X | ||||
| Book Value Per Share | 2.51 X | ||||
| Cash Flow From Operations | (48.45 M) | ||||
| Short Ratio | 0.23 X | ||||
| Earnings Per Share | (1.66) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 0.5 | ||||
| Number Of Employees | 204 | ||||
| Beta | 1.25 | ||||
| Market Capitalization | 61.08 M | ||||
| Total Asset | 161.46 M | ||||
| Retained Earnings | (259.95 M) | ||||
| Working Capital | 128.64 M | ||||
| Net Asset | 161.46 M |
About Achilles Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Achilles Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Achilles Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Achilles Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -5.1 M | -4.8 M | |
| Cost Of Revenue | 5.4 M | 2.8 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Achilles Therapeutics Piotroski F Score and Achilles Therapeutics Altman Z Score analysis. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.